Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00767689 · ClinicalTrials.gov registry record · NA
Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Capecitabine Chemotherapy
A NA study, sponsored by Cook County Health.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT00767689 is a NA study that was terminated before completion, run by Cook County Health. The registered enrollment target is 6 participants.
The verdict
NCT00767689, a NA study, was terminated before completion, sponsored by Cook County Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
Capecitabine (Xeloda) a drug in cancer therapy. Its use is limited often by its toxicities. This study is asking if vitamin B6 can prevent one of the common toxicities of xeloda which is numbness and/or rash of the hands and feet, a condition called Hand and Foot syndrome. patients , starting capecitabine chemotherapy for their cancer, will participate in this study at John H. Stroger Jr. Hospital of Cook County. They will be randomized to receive either vitamin B6 or a placebo. investigators and patients will be blinded to the intervention.
Interventions
- DRUG placebo
- DRUG Vitamin B 6
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2006-03-21 |
| Est. Completion | 2010-03-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00767689
The ClinicalTrials.gov registry entry for NCT00767689 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cook County Health, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00767689 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00767689 about?
NCT00767689 is a clinical study titled "Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Capecitabine Chemotherapy". Capecitabine (Xeloda) a drug in cancer therapy. Its use is limited often by its toxicities. This study is asking if vitamin B6 can prevent one of the common toxicities of xeloda which is numbness and/or rash of the hands and feet, a condition called Hand and Foot syndrome. patients , starting capeci...
What is the current status of trial NCT00767689?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2006-03-21. Estimated completion is 2010-03-17.
What interventions are being tested in trial NCT00767689?
The interventions under investigation include: placebo (DRUG), Vitamin B 6 (DRUG).
Who is sponsoring clinical trial NCT00767689?
This trial is sponsored by Cook County Health, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.